Upgraded heart failure therapy leads to an improved outcome of dilated cardiomyopathy in infants and toddlers
- PMID: 25498517
- DOI: 10.1017/S1047951114002406
Upgraded heart failure therapy leads to an improved outcome of dilated cardiomyopathy in infants and toddlers
Abstract
Objective: Dilated cardiomyopathy is a leading cause of cardiac death in children. Approximately 30% of children die or need cardiac transplantation in the first year after establishing the diagnosis. New strategies are needed to improve the outcome in this high-risk patient population.
Method and results: We present our experience in 38 patients below the age of three years, who were diagnosed with dilated cardiomyopathy and who were treated at our institution between 2006 and 2012. The treatment strategy involved institution of β-blockers and angiotensin-converting enzyme inhibitors as soon as feasible. In selected cases, pulmonary artery banding or intracoronary autologous bone marrow-derived cell therapy was performed. The median age at presentation was six months (range 1-26 months). The median follow-up age was 16 months (range 2-80 months). Kaplan-Meier analysis of survival after dilated cardiomyopathy diagnosis revealed a one-year survival of 97% and a five-year survival of 86%. The rate of freedom from death or heart transplantation was 82% at one year and 69% at five years. Surviving patients who were free of transplantation, at the follow-up at 25 months (3-80 months), showed a significant improvement in left ventricular ejection fraction (from 19±11 to 46±16%) and left ventricular end-diastolic diameter (z-score from 4.6±2.4 to 1.4±1.6). In addition, the levels of B-type natriuretic peptide improved significantly (from 3330±3840 to 171±825 pg/ml).
Conclusion: Our data suggest that the clinical approach described here may result in a markedly improved medium-term outcome in young children with dilated cardiomyopathy. Further studies are required to evaluate whether these approaches reduce end-points such as transplantation or death.
Keywords: Dilated cardiomyopathy; angiotensin-converting enzyme inhibitor; children; heart failure; pulmonary artery banding; β-blocker.
Similar articles
-
Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.Circ Heart Fail. 2013 Sep 1;6(5):913-21. doi: 10.1161/CIRCHEARTFAILURE.112.000120. Epub 2013 Jul 25. Circ Heart Fail. 2013. PMID: 23888044
-
Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.J Cardiovasc Pharmacol. 2003 Jan;41 Suppl 1:S5-10. J Cardiovasc Pharmacol. 2003. PMID: 12688389
-
Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up.Circ Res. 2013 Jan 4;112(1):165-73. doi: 10.1161/CIRCRESAHA.112.276519. Epub 2012 Oct 12. Circ Res. 2013. PMID: 23065358 Clinical Trial.
-
Current management of pediatric dilated cardiomyopathy.Curr Opin Cardiol. 2010 Mar;25(2):80-7. doi: 10.1097/HCO.0b013e328335b220. Curr Opin Cardiol. 2010. PMID: 20019605 Review.
-
Sudden cardiac death in dilated cardiomyopathy -- therapeutic options.Herz. 2002 Dec;27(8):750-9. doi: 10.1007/s00059-002-2425-0. Herz. 2002. PMID: 12574892 Review.
Cited by
-
Advances in heart failure therapy in pediatric patients with dilated cardiomyopathy.Heart Fail Rev. 2018 Jul;23(4):555-562. doi: 10.1007/s10741-018-9692-1. Heart Fail Rev. 2018. PMID: 29564593 Review.
-
"Nihilism" of chronic heart failure therapy in children and why effective therapy is withheld.Eur J Pediatr. 2016 Apr;175(4):445-55. doi: 10.1007/s00431-016-2700-3. Epub 2016 Feb 19. Eur J Pediatr. 2016. PMID: 26895877 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical